New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.
The U.S. FDA declined to approve Pain Therapeutics Inc.’s abuse-deterrent opioid treatment Remoxy for the fourth time.
An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.
GW Pharmaceuticals Plc’s epilepsy treatment Epidiolex secured FDA marketing clearance, becoming the first cannabis-based drug to be approved in the United States.
China’s drug control agency on Monday said the United States should do more to cut its demand for opioids to tackle the use of the synthetic drug fentanyl, but it vowed to step up cooperation after Chinese production of the substance was blamed for fueling the U.S. opioid crisis.
Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.
AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.
Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.
The head of the World Health Organization cautioned against declaring victory too early in Congo’s Ebola epidemic, despite encouraging signs that it may be brought under control.
Nektar Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the new molecular entity NKTR-181, a mu-opioid agonist for pain relief. The company also inked a non-exclusive clinical collaboration deal with Syndax Pharmaceuticals to develop Nektar’s NKTR-214, a CD122-biased agonist in combination with entinostat, Syndax’s HDAC inhibitor in metastatic melanoma.
A global coalition set up during 2017 to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.
Litigation against OxyContin maker Purdue Pharma LP intensified as six more U.S. states announced lawsuits.
The U.S. Justice Department sought court permission to participate in settlement negotiations aimed at resolving lawsuits by state and local governments against opioid manufacturers and distributors.
Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests.
The U.S. Justice Department asked a federal judge overseeing hundreds of lawsuits against opioid manufacturers and distributors to give it 30 days to decide whether to participate in the litigation.
U.S. President Donald Trump called for a federal lawsuit against opioid companies and stiffer penalties for drug dealers, arguing that the government must take a strong approach to combat an opioid addiction epidemic.
Britain’s Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.
Five opioid manufacturers including OxyContin maker Purdue Pharma LP paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report.
OxyContin maker Purdue Pharma LP has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways that drugmakers market addictive painkillers.
Maryland’s attorney general filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc. as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.